Health
STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
Publication: STAT
Author: Allison DeAngelis
Source published: 05/10/2026, 08:30:00 UTC
Briefing created: 05/10/2026, 08:39:30 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/10/2026, 08:36:25 UTC.
Briefings
Recent clinical trials involving mRNA cancer vaccines have shown promising results in slowing melanoma recurrence, sparking renewed interest in the technology. Merck and Moderna reported in August that combining their vaccine with existing treatments reduced cancer return rates. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, highlighted the potential for further development. However, the specific cancers targeted and long-term efficacy remain under investigation. The study was published in October 2026, and results are based on limited clinical data.
Key points
- Merck and Moderna reported in August 2026 that adding their mRNA vaccine to existing treatments slowed melanoma recurrence.
- Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, noted the vaccine's potential for further drug development.
Context and limitations
Results are based on limited clinical data from August 2026, and long-term efficacy and specific cancer targets remain under investigation.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/10/2026, 08:39:30 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeifpeosmblhg767gmjyvvr34emrs33awy6vtjpgogy2feciwhrlcfa